PCSK9 Inhibitor Price Reductions and Medicare Part D Utilization and Spending
This cross-sectional study evaluates price reductions and subsequent Medicare Part D utilization and spending for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Authors
- J Doshi
- Matthew J. Klebanoff (ORCID: https://orcid.org/0000-0002-5081-063X)
- Maya Merchant (ORCID: https://orcid.org/0009-0000-5385-8674)
- Pengxiang Li
- Dhruv S. Kazi
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Deaconess Hospital (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JAMA Cardiology
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1001/jamacardio.2026.1931
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00